The GHRP-2 CJC-1295 5mg x 5 Kit from Peptide Sciences provides five 5mg vials each of GHRP-2 and CJC-1295 without DAC.
High-Output GH Research
Pairing the potent GHRP-2 with a stabilised GHRH analogue gives one of the strongest GH responses among peptide combinations. Separate vials allow ratio and timing experiments that a pre-mixed blend cannot.
GHRP-2 CJC-1295 5mg x 5 Kit Specifications
| Property | Value |
|---|---|
| Active 1 | GHRP-2, 6-amino-acid ghrelin-receptor agonist |
| Active 1 pack | 5 mg per vial × 5 vials |
| Active 2 | CJC-1295 (No DAC), 30-amino-acid modified GHRH analogue |
| Active 2 pack | 5 mg per vial × 5 vials |
| Combined kit total | 50 mg total across the kit |
| Supplied form | Lyophilised powder, sealed vials |
| Purity | each active greater than 99 percent (HPLC verified) |
| Storage | 2 to 8 degrees Celsius lyophilised; minus 20 degrees Celsius long-term |
Using the 5 x 5 Kit
A mid-size kit for synergy and ratio studies.
Quality Control, COA and Shipping
Quality documentation matters for reproducible research. Every vial is traceable to a lot number, every lot carries an HPLC chromatogram and mass-spectrometry report, and orders are dispatched quickly from the USA in discreet, temperature-protected packaging.
Related Research Compounds
Researchers working with GHRP-2 and CJC-1295 often compare results with these catalog compounds:
- GHRP-2 (5mg x 10), CJC-1295 no DAC (5mg x 10)
- CJC-1295 (No DAC), GHRP-2 10mg (Blend)
- GHRP-2 5mg
- Follistatin 315 1mg
Explore the full Growth Hormone Peptides collection, browse the complete Peptide Sciences research peptide catalog, or review published literature on GHRP-2 and CJC-1295 in PubMed.
Research use only. This product is sold strictly for in-vitro laboratory research and development by qualified professionals. It is not for human or veterinary use, not a drug, food or cosmetic, and has not been evaluated by the FDA to diagnose, treat, cure or prevent any disease. Buyers must be 21+ and comply with all applicable laws.
Reviews
There are no reviews yet.